Mittmann
Gert Mittmann, Mockmuhl DE
Patent application number | Description | Published |
---|---|---|
20150202753 | HAND TOOL, IN PARTICULAR A SOLDERING GUN, WITH LIGHTS - The invention relates to a hand tool, in particular a soldering gun, having at least one handle and a tool element protruding therefrom with an actuating end section on the free end. The hand tool also has more than one light for illuminating an installation location of the hand tool. | 07-23-2015 |
Karin Mittmann, M¨nster DE
Karin Mittmann, Munster DE
Patent application number | Description | Published |
---|---|---|
20090239935 | RNA-HELICASE AS A MARKER FOR RARE TUMORS - Method for the diagnosis of diseases in a mammal, preferably in a human, wherein a probe from the mammal is examined with a view to an elevated level of RNA helicase and the elevated level of RNA helicase indicates the disease. The disease refers to esophagus carcinoma, pancreas carcinoma, stomach carcinoma, hepatocellular carcinoma, hepatoblastoma and cholangiocellular carcinoma. | 09-24-2009 |
20110110856 | Optimized Adhesin Fragments And Corresponding Nanoparticles - The invention relates to optimized adhesins and nanoparticles to which said adhesins are bound. The invention furthermore relates to providing said nanoparticles by way of in vivo contrast agents, in particular for the diagnosis of bowel cancer. | 05-12-2011 |
Katrin Mittmann, Jena DE
Patent application number | Description | Published |
---|---|---|
20090035373 | PHARMACEUTICAL COMPOSITION FOR CONTRACEPTION AND BLOOD PRESSURE REGULATION, KIT FOR CONTRACEPTION CONTAINING SAME AND METHOD OF PRODUCTION OF SAME - The pharmaceutical composition for contraception and regulating blood pressure includes daily dosage units, which contain 2.0 mg of dienogest and 0.030 mg of ethinyl estradiol, 2.0 mg of dienogest and 0.020 mg of ethinyl estradiol, or 1.5 mg of dienogest and 0.015 mg of ethinyl estradiol, together with at least one excipient and/or carrier. Each daily dosage unit may be a coated tablet for oral administration consisting of a tablet core and a coating around the core. The coating contains all of the ethinyl estradiol and a part of the dienogest, which are released in a non-retarded fashion. The tablet core contains another part of the dienogest that is released in a retarded fashion. The risk of folate deficiency-induced congenital malformations in the event of pregnancy may be reduced by including (6S)-5-methyltetrahydrofolate in each daily dosage unit. A kit for a 28-day cycle is also disclosed. | 02-05-2009 |
20090035374 | METHOD OF MAKING A SINGLE-STAGE PHARMACEUTICAL PREPARATION FOR ORAL THERAPY TO REGULATE BLOOD PRESSURE AND KIT CONTAINING SAME - The single-stage oral contraceptive preparation contains at least 21 daily dosage units, which each contain a contraceptive combination of 2.0 mg of dienogest (not an aidosterone antognist) and 0.030 mg of ethinyl estradiol, of 2.0 mg of dienogest and 0.020 mg of ethinyl estradiol, of 2.0 mg of dienogest and 0.015 mg of ethinyl estradiol, or of 1.5 mg of dienogest and 0.015 mg of ethinyl estradiol, together with one or more pharmaceutically acceptable excipients and/or carriers, and at the most 7 daily dosage units containing a placebo or no active ingredients. The contraceptive preparation also regulates the blood pressure, raising low blood pressure and lowering mildly elevated blood pressure, during its administration for contraception. It is especially suitable for long-duration use as a contraceptive preparation without risk of negatively influencing the blood pressure. | 02-05-2009 |
20090099144 | ORAL CONTRACEPTION (LONG-CYCLE REGIMEN AND 21-DAYS-REGIMEN WITH 30 MG ETHINYLESTRADIOL AND 2 MG DIENOGEST) WITHOUT TREATMENT OF THROMBOSIS/HEMOSTASIS - The kit for long-cycle administration of a monophasic oral contraceptive preparation without affecting blood pressure advantageously consists of 84 daily dose units, which each contains a combination of 2.0 mg of dienogest and 0.030 mg of ethinyl estradiol, and 7 daily dose units that do not contain any active contraceptive agent or contain a placebo. During long-cycle administration over the course of a year using four 91-day cycle kits, no significant differences in the resulting hemostatic variables in comparison to those obtained during conventional administration with 28-day cycle kits, which each contain 21 daily dose units each containing the combination and 7 daily dose units without the combination or with a placebo, were observed at any time. | 04-16-2009 |
20090099145 | Process for Producing a Single-phase Pharmaceutical Preparation for Limiting/Reducing the Risk of Deep Venous Thrombosis in Association with Oral Contraception - Single-phase oral contraceptives containing a combination of 2.0 mg of dienogest and 0.030 mg of ethinylestradiol or 2.0 mg of dienogest and 0.020 mg of ethinylestradiol in n×21 daily dose units followed by n×21 of at the most 7 daily hormone-free or placebo-containing dose units, where n equals 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 and 17, bring about a limitation/reduction of the risk of deep venous thrombosis in combination with oral contraception. | 04-16-2009 |
Mario Mittmann, Owen DE
Patent application number | Description | Published |
---|---|---|
20120244449 | CONTAINER ARRANGEMENT FOR A FUEL CELL SYSTEM, AND METHOD FOR INTRODUCING AN ION EXCHANGE MODULE IN A COOLANT CONTAINER - A container arrangement ( | 09-27-2012 |
20130224617 | Coolant Circuit for a Fuel Cell System and Method for Changing out Ion Exchanger Material - A coolant circuit for a fuel cell system of a motor vehicle includes an ion exchanger material arranged in at least one component of the coolant circuit that is flowed through by coolant during the cooling operation. The ion exchanger material is fixed to an internal side of a wall of the at least one component. During an exchange of the ion exchanger material, the entire component is exchanged and replaced by a replacement component. | 08-29-2013 |
20130224619 | Coolant Circuit for a Fuel Cell System, and Method for Fluidically Coupling an Ion Exchange Module to a Component of a Coolant Circuit - A coolant circuit for a fuel cell system of a motor vehicle includes an ion exchange module fluidically coupled to a component of the coolant circuit, which is flowed through by coolant during a cooling operation. The ion exchange module is fixed to an external wall of the component. A fastening element couples the ion exchange module fluidically to the component. | 08-29-2013 |
20140072894 | COOLANT CYCLE FOR A FUEL CELL SYSTEM AND METHOD FOR OPERATING A COOLANT CYCLE - A coolant circuit ( | 03-13-2014 |
20150017560 | Functional Module for a Coolant Circuit of a Fuel Cell System and Method for Producing a Functional Module and Container for a Coolant Circuit of a Fuel Cell System - A functional module for a coolant circuit of a vehicle fuel cell system includes a container having an ion-exchange material and a pump device for the coolant fluidically coupled to each other in such a manner that a coolant inlet and a coolant outlet of the pump device are connected to a coolant outlet and a coolant inlet of the container. The container surrounds at least one region of the pump device that has a conveying unit of the pump device at least in certain areas around the outer circumference. | 01-15-2015 |
Michael P. Mittmann, Palo Alto, CA US
Patent application number | Description | Published |
---|---|---|
20120151746 | Apparatuses, Systems and Methods for the Attachment of Substrates to Supports with Light Curable Adhesives - Disclosed are apparatuses, systems and methods for attachment of substrates to supports. Disclosed are integrated pick-and-place curing apparatuses and systems and methods for using them. Integration of pick-and-place and curing functionalities provides higher efficiency and effectiveness compared to approaches which separate the two functions. Also disclosed are systems and methods for simultaneous attachment of a plurality of substrates to a support. Substrates include, within certain embodiments, arrays of biological polymers which are unaffected by the disclosed pick-and-place curing approaches. | 06-21-2012 |
20120196381 | Miniaturized Microparticles - An encoded microparticle having a spatial code is provided; and a set of encoded microparticles possessing subsets each provided with a distinguishable spatial code, wherein the codes comply with a pre-determined coding scheme. Presented are also methods of using the encoded microparticles in various biological assays, such as various multiplex assays and visualizing them by creating a digital image of the encoded microparticles and determining whether false positives are present. Further are provided methods of manufacture of the encoded microparticles which employ ferromagnetic nanoparticles applied using spin-on-glass techniques. | 08-02-2012 |
Rudolf Mittmann, Tacherting DE
Patent application number | Description | Published |
---|---|---|
20140336979 | POSITION-MEASURING DEVICE - A position-measuring device includes a measuring transducer configured to carry out a position measurement. The position-measuring device has at least one memory having stored parameter data defining an active configuration under which the position-measuring device is operable. The at least one memory further has data and instructions useable to activate at least one further configuration under which the position-measuring device is operable. | 11-13-2014 |
Stefan Mittmann, Muenchen DE
Patent application number | Description | Published |
---|---|---|
20150218739 | Module Element for Driving and Retaining Braiding Bobbin Carriers and a Braiding Device - A module element for driving and retaining braiding bobbin carriers on a predetermined bobbin path has at least one base element that can rotate about an axis of rotation, and at least one retaining element that is formed integrally with the base element. The retaining element is configured to releasably hold at least one braiding bobbin carrier offset from the rotary axis. | 08-06-2015 |
Ulrich Mittmann, Freiburg DE
Patent application number | Description | Published |
---|---|---|
20090018125 | Pharmaceutical Composition and Its Use - Polyunsaturated fatty acid (“PUFA”) or a pharmacologically acceptable salt or derivative thereof (such as EPA and/or DHA) is used in combination with at least one of an immunosuppressive agent or an antineoplastic agent, said agent(s) having at least one amino acid residue, or a pharmacologically acceptable salt or derivative thereof (such as methotrexate or cyclosporin) in the treatment of conditions involving acutely or chronically inadequate immune response. Specific conditions that may be treated include chronic inflammatory diseases (e.g. Crohn's disease and ulcerative colitis) and tumour diseases (e.g. bowel cancer and prostate cancer). One advantage of preferred embodiments of the invention is that bioavailability of immunosuppressive or antineoplastic agents is increased. | 01-15-2009 |